PMID- 34036101
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20210920
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2021
DP  - 2021
TI  - A Novel Review of Homocysteine and Pregnancy Complications.
PG  - 6652231
LID - 10.1155/2021/6652231 [doi]
LID - 6652231
AB  - Homocysteine (Hct) is a substance produced in the metabolism of methionine. It is 
      an essential type of amino acid gained from the daily diet. 
      Methylenetetrahydrofolate reductase (MTHFR) gene mutation is related to elevated 
      total homocysteine (tHct) expressions, in particular, among women with low folate 
      intake. Hyperhomocysteinemia (HHct) is caused by numerous factors, such as 
      genetic defects, lack of folic acid, vitamin B(6) and B(12) deficiency, 
      hypothyroidism, drugs, aging, and renal dysfunction. Increased Hct in peripheral 
      blood may lead to vascular illnesses, coronary artery dysfunction, 
      atherosclerotic changes, and embolic diseases. Compared to nonpregnant women, the 
      Hct level is lower in normal pregnancies. Recent studies have reported that HHct 
      was associated with numerous pregnancy complications, including recurrent 
      pregnancy loss (RPL), preeclampsia (PE), preterm delivery, placental abruption, 
      fetal growth restriction (FGR), and gestational diabetes mellitus (GDM). Besides, 
      it was discovered that neonatal birth weight and maternal Hct levels were 
      negatively correlated. However, a number of these findings lack consistency. In 
      this review, we summarized the metabolic process of Hct in the human body, the 
      levels of Hct in different stages of normal pregnancy reported in previous 
      studies, and the relationship between Hct and pregnancy complications. The work 
      done is helpful for obstetricians to improve the likelihood of a positive outcome 
      during pregnancy complications. Reducing the Hct level with a high dosage of 
      folic acid supplements during the next pregnancy could be helpful for females who 
      have suffered pregnancy complications due to HHct.
CI  - Copyright (c) 2021 Chuce Dai et al.
FAU - Dai, Chuce
AU  - Dai C
AUID- ORCID: 0000-0001-6183-0882
AD  - China Medical University, Shenyang, Liaoning, China.
FAU - Fei, Yiming
AU  - Fei Y
AUID- ORCID: 0000-0002-9844-6777
AD  - China Medical University, Shenyang, Liaoning, China.
FAU - Li, Jianming
AU  - Li J
AUID- ORCID: 0000-0001-8277-0137
AD  - China Medical University, Shenyang, Liaoning, China.
FAU - Shi, Yang
AU  - Shi Y
AUID- ORCID: 0000-0002-1390-1217
AD  - China Medical University, Shenyang, Liaoning, China.
FAU - Yang, Xiuhua
AU  - Yang X
AUID- ORCID: 0000-0002-4949-131X
AD  - Department of Obstetrics, The First Hospital of China Medical University, 
      Shenyang, Liaoning, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210506
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 8059-24-3 (Vitamin B 6)
RN  - 935E97BOY8 (Folic Acid)
RN  - P6YC3EG204 (Vitamin B 12)
SB  - IM
MH  - Abortion, Habitual
MH  - Aging
MH  - Birth Weight
MH  - Diabetes, Gestational
MH  - Dietary Supplements
MH  - Female
MH  - Fetal Growth Retardation
MH  - Folic Acid/blood
MH  - Homocysteine/*blood/metabolism
MH  - Humans
MH  - Hyperhomocysteinemia/blood/metabolism
MH  - Placenta
MH  - Pre-Eclampsia
MH  - Pregnancy
MH  - *Pregnancy Complications
MH  - Vitamin B 12/blood
MH  - Vitamin B 12 Deficiency
MH  - Vitamin B 6/blood
MH  - Vitamin B 6 Deficiency
PMC - PMC8121575
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/05/27 06:00
MHDA- 2021/09/21 06:00
PMCR- 2021/05/06
CRDT- 2021/05/26 06:58
PHST- 2020/12/19 00:00 [received]
PHST- 2021/04/26 00:00 [accepted]
PHST- 2021/05/26 06:58 [entrez]
PHST- 2021/05/27 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2021/05/06 00:00 [pmc-release]
AID - 10.1155/2021/6652231 [doi]
PST - epublish
SO  - Biomed Res Int. 2021 May 6;2021:6652231. doi: 10.1155/2021/6652231. eCollection 
      2021.